Literature DB >> 19895344

High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay.

Shripad V Bhagwat1, Jennifer Kahler, Yan Yao, Paul Maresca, Maureen Brooks, Andy Crew, Michael Boisclair, Jonathan A Pachter.   

Abstract

A high-throughput chemiluminescence and ELISA-based biochemical assay to identify mTORC1/mTORC2 kinase inhibitors is described. These mTOR complexes were isolated from HeLa whole cell lysate using mTOR antibodies and in-well immunoprecipitation. The integrity and purity of the mTORC1 and mTORC2 immunocomplexes were confirmed by western blotting. Full-length recombinant 4E-BP1 was used as a substrate and the catalytic activity was measured by detection of p4E-BP1 [T37/46] by a chemiluminescence method. The performance of this assay that can be used to identify dual mTORC1 and mTORC2 kinase inhibitors in a high-throughput 384-well format is described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895344     DOI: 10.1089/adt.2008.0183

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  1 in total

1.  Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.

Authors:  Beverly L Falcon; Sharon Barr; Prafulla C Gokhale; Jeyling Chou; Jennifer Fogarty; Philippe Depeille; Mark Miglarese; David M Epstein; Donald M McDonald
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.